Enveda Biosciences closed a $150 million Series D financing round, increasing its total funding to over $500 million, aimed at advancing its diverse pipeline of natural product-inspired therapeutics. Utilizing AI-driven platforms to mine complex biological datasets, Enveda focuses on inflammatory and immunology diseases with plans to initiate multiple clinical trials, including a Phase 1b for atopic dermatitis. Strategic investment from global biotech and tech funds supports their ambition to harness nature’s chemical diversity for novel drug candidates.